Next-gen antibiotic developed by Monash University enters clinical trials
In a critical step towards addressing an urgent unmet medical need due to infections caused by antibiotic-resistant bacteria - also known as ‘superbugs’ - a new antibiotic (QPX9003) discovered by Monash University researchers has entered Phase 1 clinical trials in the United States.
The trials have been initiated by the US-based biopharmaceutical company Qpex Biopharma Inc. (Qpex) who have worked in collaboration with Monash to drive clinical development of the drug.
QPX9003, which was discovered at the Monash Institute of Pharmaceutical Sciences (MIPS) and the Monash Biomedicine Discovery Institute (BDI), is an intravenously-administered synthetic next-generation polymyxin for treating Gram-negative ‘superbug’ infections.
Read full story here.